RTL8 interacts with the NTD lobe of PEG10 capsid. by Will Campodonico (20485651)

Factor loadings based on a principal components analysis with Varimax rotation for 33 music styles in a frequency of listening scale. by Oswaldo Lorenzo-Quiles (9443753)

Boxplot of the log10 transformed expression values for selected GO terms. by Michael Schneider (1806265)

Boxplot of the log10 transformed expression values for selected GO terms. by Michael Schneider (1806265)

Correlations between volumetric decrease in rACC and average cortisol levels for patients (A) and controls (B) and correlations between volumetric decrease in rACC and the combined... by Michael T. Treadway (371126)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participa... by Joseph Kamgno (81039)

PEG10-derived VLPs are naturally released by human cells. by Will Campodonico (20485651)

Chlorophyll content in L10 after 42 days of treatment. by Baolin Kan (12936933)

Fig 7 - by Yasunori Aoki (339027)

Reactive oxygen species formation in aorta. by Haroldo A. Toque (447341)

Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

“…CARM1 (coactivator-associated arginine methyltransferase 1), which belongs to type I PRMTs (protein arginine methyltransferases), is a potential therapeutic target for treatment of multiple cancers. In this study, we first identified several hit compounds against CARM1 by structure-based virtual screening (IC₅₀ = 35.51 ± 6.68 to 68.70 ± 8.12 μM) and then carried out chemical structural optimizations, leading to six compounds with significantly improved activities targeting CARM1 (IC₅₀ = 18 ± 2 to 107 ± 6 nM). …”

A screenshot from low motivation experimental runs, during interruption. by Ezel Üsten (16548547)

A screenshot from high motivation experimental runs, during interruption. by Ezel Üsten (16548547)

Simulation of the average densities/concentrations of the variables for model (2)–(21) with ENZ, Sip-T, anti-PD-1 (<i>A</i>₁) and anti-CTLA-4 (<i>A</i>₄). by Nourridine Siewe (5081834)

“…All parameters are as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0262453#pone.0262453.s001" target="_blank">S1 File</a>. …”

Reducing health inequalities with interventions targeting behavioral factors among individuals with low levels of education - A rapid review by Andreas Vilhelmsson (423357)

Methods of assessment of the glottic gap using a rigid endoscope. by Ikuo Mikoshiba (9312007)

Top 10 genes associated to smoking or plaques. by Ricardo A. Verdugo (276036)

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

“…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC₅₀ at 2.1 μM. …”

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

“…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC₅₀ at 2.1 μM. …”

Optimized parameters for mesopic and photopic condition used in the study. by C. Vijay Reena Durai (14498259)

Subjects: